Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-08-19

FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Ambrisentan from Mylan Pharmaceuticals Inc., approving a generic version of the drug used to treat pulmonary arteria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)